Prognostic significance of clinical parameters and Epstein-Barr virus infection in non-endemic undifferentiated carcinoma of nasopharyngeal type: a Serbian report.
Undifferentiated carcinoma of nasopharyngeal type (UCNT) is very rare tumour in Serbia, like in most of the countries of Europe, with incidence less than 0.5 per 100,000 people per year. The aim of this study was to assess the presence of Epstein-Barr virus (EBV) in the UCNT of a non-endemic population in Serbia and identify the main clinical parameters that interfere with patients' survival rate. This study included 102 patients with UCNT who were diagnosed between 1996 and 2003. Biopsies were analysed for EBV-encoded RNA (EBER) by in situ hybridization of tumour tissue microarray. Of 102 patients, 76 were men and 26 were women with ages ranging between 18 and 82 years (median 52.5, mean 53.0±14.1). Survival rates were 80, 39 and 31% for one, three and five years, respectively. Ninety-three of 102 cases were EBER positive (92%). Factors with unfavourable prognostic values were age over 50 years at the time of diagnosis, advanced clinical stage, therapy other than chemoradiotherapy and EBER negative status. In regard to the clinical data, EBER expression in UCNT was shown to be a strong independent predictor of overall and progression-free survival. To our knowledge, the current report constitutes the largest European non-endemic series of UCNT samples from a single institution with correlation between survival and clinical parameters/EBER status.
Terzic
T T
TT
Institute of Pathology, School of Medicine, University of Belgrade, Dr. Subotica 1, 11000, Belgrade, Serbia.
Boricic
M I
MI
Pendjer
I P
IP
Ruzic Zecevic
D T
DT
Tomanovic
N R
NR
Brasanac
D C
DC
Boricic
I V
IV
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D002277:Carcinoma; D002454:Cell Differentiation; D018572:Disease-Free Survival; D020031:Epstein-Barr Virus Infections / Q000150:complications* / Q000453:epidemiology* / Q000401:mortality; D005260:Female; D006801:Humans; D017403:In Situ Hybridization; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000401:mortality* / Q000473:pathology / Q000821:virology*; D009367:Neoplasm Staging; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D055771:Serbia / Q000453:epidemiology; D046888:Tissue Array Analysis; D055815:Young Adult
Semin Cancer Biol. 2002 Dec;12(6):451-62
12450731
Swiss Med Wkly. 2010 May;140(19-20):273-9
19950040
Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2356-65
18768504
Pathol Biol (Paris). 2009 Jul;57(5):427-9
18835109
Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1107-16
15752890
Vojnosanit Pregl. 2007 Jul;64(7):459-62
17821920
Int J Cancer. 2009 Sep 15;125(6):1358-64
19536817
J Mol Diagn. 2008 Jul;10(4):279-92
18556771
Otolaryngol Head Neck Surg. 2006 Apr;134(4):639-45
16564389
J Transl Med. 2008 Jan 03;6:1
18171482
Cancer Res. 2006 Jan 15;66(2):693-700
16423998
Eur Arch Otorhinolaryngol. 2009 Jun;266(6):833-8
18830701
Virchows Arch. 2008 Apr;452(4):411-4
18299891
Clin Cancer Res. 2006 Oct 1;12(19):5726-32
17020977
Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1765-77
17035381
Eur J Cancer. 1998 Dec;34(14 Spec No):2162-6
10070282
Vojnosanit Pregl. 2009 Jun;66(6):473-6
19583146
Acta Otolaryngol. 2001 Dec;121(8):884-95
11813890
Cancer. 2002 Apr 1;94(7):1997-2006
11932902
Am J Epidemiol. 2007 Feb 1;165(3):271-8
17090616
Virus Res. 2006 Jan;115(1):85-90
16139912
J Cancer Res Ther. 2009 Apr-Jun;5(2):102-6
19542665